Foghorn Therapeutics (FHTX) Projected to Post Earnings on Thursday

Foghorn Therapeutics (NASDAQ:FHTX) is projected to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Foghorn Therapeutics to post earnings of ($0.30) per share and revenue of $9.50 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Foghorn Therapeutics Stock Performance

Shares of NASDAQ:FHTX opened at $5.80 on Thursday. The firm has a market capitalization of $327.99 million, a PE ratio of -5.13 and a beta of 3.02. Foghorn Therapeutics has a 52-week low of $2.94 and a 52-week high of $6.95. The firm has a fifty day moving average of $5.62 and a 200 day moving average of $5.02.

Hedge Funds Weigh In On Foghorn Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. purchased a new stake in Foghorn Therapeutics in the fourth quarter worth $58,000. XTX Topco Ltd bought a new stake in shares of Foghorn Therapeutics during the 4th quarter valued at about $85,000. Millennium Management LLC increased its position in shares of Foghorn Therapeutics by 16.7% during the fourth quarter. Millennium Management LLC now owns 208,565 shares of the company’s stock valued at $1,126,000 after buying an additional 29,774 shares during the period. Jump Financial LLC bought a new position in Foghorn Therapeutics in the fourth quarter worth about $130,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in Foghorn Therapeutics by 350.3% in the fourth quarter. Public Employees Retirement System of Ohio now owns 14,269 shares of the company’s stock worth $77,000 after buying an additional 11,100 shares during the period. Institutional investors own 61.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on FHTX. BTIG Research initiated coverage on Foghorn Therapeutics in a research note on Thursday, December 18th. They issued a “buy” rating and a $11.00 target price for the company. Wedbush restated an “outperform” rating and issued a $10.00 price objective on shares of Foghorn Therapeutics in a report on Thursday, November 6th. Stifel Nicolaus began coverage on shares of Foghorn Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Foghorn Therapeutics in a research report on Thursday, January 22nd. Finally, Guggenheim initiated coverage on Foghorn Therapeutics in a research note on Friday, November 7th. They set a “buy” rating and a $12.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.13.

About Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.